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ABSTRACT
In this study, we analyze the effect of several retinoids on the
expression of nonsteroidal anti-inflammatory drug-activated
gene (NAG-1) in normal human tracheobronchial epithelial
(HTBE) cells and several lung carcinoma cell lines. The retinoid
6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxy-
lic acid (AHPN) greatly enhances the expression of NAG-1
mRNA and protein in a time- and dose-dependent manner in
human lung adenocarcinoma H460 cells and several other car-
cinoma cell lines. This induction was specific for AHPN be-
cause retinoic acid, a retinoic acid receptor-, and a retinoid X
receptor pan-agonist were unable to induce NAG-1, suggesting
that this induction is not mediated through activation of retinoid
receptors. Although NAG-1 is a p53-responsive gene, AHPN-
induced NAG-1 expression does not require p53. The induction
of NAG-1 expression by AHPN is caused at least in part by an
8-fold increase in the stability of NAG-1 mRNA. In contrast to
carcinoma cells, NAG-1 expression is effectively induced by
retinoic acid and the RAR-selective pan-agonist in normal
HTBE cells and accompanies the inhibition of squamous dif-
ferentiation and the initiation of normal differentiation. In vivo,
NAG-1 expression was observed in the normal tracheobron-
chial epithelium, whereas no expression was found in either
squamous metaplastic tracheal epithelium or in sections of
human lung tumors. Our results suggest that the induction of
NAG-1 expression by retinoids in normal HTBE and lung car-
cinoma cells is regulated by distinct mechanisms and is asso-
ciated with different biological processes. The linkage between
AHPN treatment and NAG-1 expression revealed in this study
provides a new mechanism for the antitumorigenic activity of
AHPN.
Retinoids play a critical role in prenatal and postnatal
development of the lung and in the maintenance of normal
homeostasis in the respiratory epithelium (Jetten et al.,
1992; Massaro and Massaro, 1997). In the tracheobronchial
epithelium retinoids are essential for the differentiation of
tracheobronchial epithelial cells into mucous and ciliated
cells (Floyd and Jetten, 1989; Jetten et al., 1992; Marvin et
al., 1992; Reddy et al., 1995; Koo et al., 1999). Retinoid
signaling pathways are also relevant to lung disease. Reti-
noic acid has been reported to reverse elastase-induced em-
physema in rats (Massaro and Massaro, 1997) and retinoid
signaling pathways are defective in human lung carcinoma
cells (Adachi et al., 1998; Nervi et al., 1991; Virmani et al.,
2000; Sun et al., 2002).
Many of the effects of retinoids are mediated by the retinoic
acid receptors (RARs) and retinoid X receptors (RXRs). Re-
cent studies have indicated that the regulation of differenti-
ation in tracheobronchial epithelial cells by retinoids is me-
diated through these signaling pathways (Nervi et al., 1991;
Koo et al., 1999). However, certain actions of retinoids, in-
cluding the inhibition of cell proliferation and induction of
apoptosis in many carcinoma cell lines by 6-[3-(1-adamantyl)-
4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN,
also named CD437), are independent of retinoid receptors
(Shao et al., 1995; Adachi et al., 1998; Rishi et al., 1999;
Sakaue et al., 1999; Sun et al., 1999, 2000, 2002; Zhao et al.,
2001; Fontana and Rishi, 2002). The precise molecular mech-
anism(s) by which AHPN induces these changes has yet to be
established.
In this study, we examine the effect of several retinoids on
the expression of the nonsteroidal anti-inflammatory drug-
activated gene-1 (NAG-1) (Baek et al., 2001a), a divergent
member of the transforming growth factor- superfamily, in
HTBE and lung carcinoma cells. NAG-1 is also referred to as
ABBREVIATIONS: RAR, retinoic acid receptor; RXR, retinoid X receptor; AHPN, 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene-carboxylic
acid, NAG-1, nonsteroidal anti-inflammatory drug-activated gene 1; HTBE, human tracheobronchial epithelial; TTAB, 4-(5,6,7,8-tetrahydro-
5,5,8,8-tetramethyl-2-anthracenyl)-benzoic acid; GPDH, glyceraldehyde-3-phosphate dehydrogenase; ERK, extracellular signal-regulated kinase;
UTR, untranslated region; TTP, tristetraproline; PD98059, 2-amino-3-methoxyflavone.
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macrophage inhibitory cytokine-1 (Bootcov et al., 1997), pla-
cental transforming growth factor- (Lawton et al., 1997),
placental bone morphogenetic protein (Hromas et al., 1997),
prostate-derived factor (Paralkar et al., 1998), and growth/
differentiation factor-15 (Bottner et al., 1999). NAG-1, like
members of the transforming growth factor- family, con-
tains a highly conserved, cysteine-rich domain of 80 residues.
NAG-1 is synthesized as a 40-kDa propeptide that dimerizes
in the endoplasmic reticulum. The inactive dimeric precursor
is cleaved by a furin-like convertase, yielding an active 28-
kDa homodimer that is secreted (Bauskin et al., 2000). Al-
though the precise functions of NAG-1 have yet to be deter-
mined, several roles for NAG-1 are beginning to emerge.
Recent studies suggested a role for NAG-1 in inflammatory
responses, apoptosis, and tumorigenesis (Bootcov et al., 1997;
Li et al., 2000; Baek et al., 2001b; Albertoni et al., 2002).
Overexpression of NAG-1 in colon carcinoma and glioblas-
toma cells has been shown to inhibit tumorigenicity in nude
mice, indicating that NAG-1 exhibits antitumor activities.
In this study, we demonstrate that AHPN is a very effec-
tive inducer of NAG-1 expression in a number of human
carcinoma cell lines. This induction is independent of p53
and is caused at least in part by an increase in the stability
of NAG-1 mRNA. In most cell lines tested, retinoic acid and
an RAR- and RXR-pan-agonist were unable to enhance
NAG-1 expression, suggesting that its induction by AHPN is
mediated through an RAR/RXR-independent mechanism. In
contrast to carcinoma cells, retinoic acid and the RAR pan-
agonist were able to induce NAG-1 expression in normal
human tracheobronchial epithelial (HTBE) cells. This induc-
tion was associated with inhibition of squamous differentia-
tion and induction of normal differentiation. Histochemical
analysis demonstrated that NAG-1 expression is associated
with the normal tracheobronchial epithelium but is absent in
squamous metaplasia. Our results suggest that the regula-
tion of NAG-1 expression by retinoids in normal HTBE and
carcinoma cells is mediated by different mechanisms. The
lack of NAG-1 induction in tumor cells by retinoic acid and
the RAR pan-agonist may be related to defects in the retinoid
signaling pathway. Previous studies demonstrated that
AHPN inhibits the tumorigenicity of lung carcinoma cells in
mice (Lu et al., 1997) and that NAG-1 can inhibit tumor
formation (Baek et al., 2001b; Albertoni et al., 2002). The
induction of NAG-1 by AHPN reported in this study provides
a novel mechanism for the antitumor activity of AHPN.
Materials and Methods
Materials. The retinoid AHPN was obtained from Dr. U. Reichert
(CIRD Galderma, Valbonne, France). The RAR-selective agonist
[SRI-6751-84/TTAB, 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-an-
thracenyl)-benzoic acid], RXR-selective agonist [SR11217, 4-[1-
(5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl-2-naphthalenyl)-2-methyl-
propenyl]-benzoic acid], and anti-AP1-selective retinoid [SR11302,
(E)-3-methyl-9-(2,6,6-trimethylcyclohexenyl)-7-(4-methyl-phenyl)-
2,4,6,8-nonatetraenoic acid] (Fanjul et al., 1994) were provided by
Dr. M. Dawson (SRI, Menlo Park, CA). All-trans retinoic acid was
obtained from F. Hoffman-La Roche (Nutley, NJ). Retinoids were
dissolved in dimethyl sulfoxide. Control cells received dimethyl sul-
foxide only. Human NAG-1 (MIC-1) protein was kindly provided by
Dr. S. N. Breit (Centre for Immunology, St. Vincent’s Hospital,
Sydney, Australia).
Cell Culture. Normal HTBE cells were obtained from Cambrex
Bio Science Walkersville (San Diego, CA). Cells were grown onto
24-mm permeable Transwell membranes (Costar, Cambridge, MA)
in a 1:1 mixture of Dulbecco’s modified Eagle’s medium and bron-
chial epithelial cell growth medium (Cambrex Bio Science Walkers-
ville) as described previously (Koo et al., 1999). Human carcinoma
cell lines were obtained from Dr. A. Gazdar (University of Texas
Southwestern Medical Center, Austin, TX) or from American Type
Culture Collection (Manassas, VA). All cell lines were mycoplasm-
free. Carcinoma cell lines were grown in RPMI 1640 medium sup-
plemented with 10% heat-inactivated fetal bovine serum, penicillin,
and streptomycin. Cells were grown in the absence or presence of
retinoids as indicated.
RNA Isolation and Northern Analysis. RNA from cultured
cells was isolated using Tri-Reagent (Sigma-Aldrich, St. Louis, MO)
according to the manufacturer’s protocol. Total RNA (30 g) was
electrophoresed through a formaldehyde 1.2% agarose gel as de-
scribed previously (Sakaue et al., 1999), blotted to a Nytran Plus
membrane (Schleicher & Schuell, Keene, NH), and UV cross-linked.
Membranes were hybridized with radiolabeled probes for NAG-1,
transglutaminase type I, and chicken glyceraldehyde-3-phosphate
dehydrogenase gene (GPDH) as reported previously (Sakaue et al.,
1999). A 602-base pair EcoRI/NotI cDNA fragment encoding human
NAG-1 was excised from IMAGE clone 1713523 (Research Genetics,
Huntsville, AL) and used as a probe for NAG-1. Hybridizations were
performed for 1 to 2 h at 68°C using QuikHyb reagent (Stratagene,
La Jolla, CA), blots were washed twice with 2 standard saline
citrate, 0.05% SDS for 15 min at room temperature, and in the final
wash with 0.5 standard saline citrate, 0.1% SDS for 30 min at
65°C. Autoradiography was carried out with Hyperfilm-MP (Amer-
sham Biosciences, Piscataway, NJ) at 70°C using double intensi-
fying screens. MUC2 mRNA was analyzed by reverse transcription-
polymerase chain reaction as described previously (Koo et al., 1999).
Western Blot Analysis. Cells were treated with retinoids in
serum-free medium. Cells were collected in sample buffer (60 mM
Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 10 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, aprotinin, and leupeptin) and phos-
phatase inhibitor mixture I and II (Sigma-Aldrich). Medium was
collected separately, concentrated with Centricon Y-10 microconcen-
trators (Millipore Corporation, Bedford, MA), and mixed with 2
sample buffer. Proteins were examined by Western blot analyses
using a specific antiserum against human NAG-1 (Baek et al.,
2001b). Peroxidase-conjugated anti-rabbit IgG (AP156P GtXRbt) (1:
20,000 dilution with 5% milk), purchased from Chemicon Interna-
tional (Temecula, CA), was used as secondary antibody. Antibodies
were diluted in phosphate-buffered saline containing 1 or 5% milk
powder and 0.05% Tween 20. Detection was carried out using Super
Signal chemiluminescent substrate; luminol and peroxide purchased
from Pierce Chemical (Rockford, IL).
Immunohistochemical Staining. Tissues were fixed in 4% for-
malin at 4°C for 16 h and then embedded in paraffin. Paraffin
sections (5 m) were deparaffinized in xylene and rehydrated
through a graded series of ethanol solutions. The sections were
incubated with blocking solution (5% milk powder, 1% bovine serum
albumin in phosphate-buffered saline) for 60 min at room tempera-
ture, followed by a 60-min incubation with a 1000-fold dilution of
anti-NAG-1 antiserum or preimmune serum in blocking solution.
Subsequently, tissue sections were incubated for 60 min with biotin-
ylated goat-anti-rabbit IgG (Jackson Laboratories, Bar Harbor,
Maine) and then with streptavidin-horseradish peroxidase (Jackson
Laboratories). Immunoreactivity was visualized using diaminoben-
zidine. The sections were counterstained with 1% methyl green.
Results
Induction of NAG-1 Expression by AHPN in Lung
Adenocarcinoma H460 Cells. Microarray analysis has
identified a number of genes that are differentially regulated
in lung carcinoma H460 cells during treatment with AHPN
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(Sakaue et al., 1999, 2001). In this study, we characterize the
expression of one of these genes, NAG-1. As shown in Fig. 1A,
AHPN treatment of H460 cells enhanced NAG-1 mRNA
expression about 16-fold. In contrast, the RAR pan-agonist
TTAB, the RXR agonist SR11217, or SR11302, a retinoid
with reported selective anti-activator protein 1 activity
(Fanjul et al., 1994), was unable to increase NAG-1 mRNA
expression in these cells. Retinoic acid also did not induce
NAG-1 in H460 cells (data not shown). These results dem-
onstrate that induction of NAG-1 is restricted to AHPN
and suggest that regulation of NAG-1 expression in H460
by AHPN is independent of the activation of RAR or RXR
receptor signaling pathways.
Induction of NAG-1 by AHPN in Other Carcinoma
Cell Lines. The induction of NAG-1 by AHPN was examined
in a number of other lung carcinoma cell lines. AHPN was
able to induce NAG-1 mRNA in adenocarcinoma A549 and
H1355, and squamous carcinoma 226 cells (Fig. 1B). A small
increase was observed in lung adenocarcinoma H441 and
small cell carcinoma H69 cells, whereas levels did not change
in adenocarcinoma Calu-6 cells. Analysis of NAG-1 expres-
sion in several other carcinoma cell types showed induction of
NAG-1 mRNA in human mammary carcinoma MCF-7, T47D,
BT549, ZR-75-1, and in prostate carcinoma LNCaP and PC3
cells. A small increase was observed in sarcoma HT1080-
p53wt and HT1080-p53mt cells. The basal level of expression
of NAG-1 was significantly higher in HT1080-p53wt contain-
ing the wild-type p53 compared with HT1080-p53mt contain-
ing a mutated p53 gene.
As demonstrated for H460 cells, the RAR pan-agonist
TTAB was unable to induce NAG-1 in lung carcinoma H441,
A549, A1355, and Calu-6, and mammary carcinoma MDA-
MB321, BT20, T-47D, and BT549 cells (Fig. 1C). However,
TTAB was able to enhance NAG-1 expression significantly in
MCF-7 and caused a weak increase in ZR-75-1 cells. These
results further support the conclusion that AHPN and TTAB
regulate NAG-1 expression by two different mechanisms.
Time- and Dose-Dependent Induction of NAG-1. As
shown in Fig. 2, AHPN induces NAG-1 mRNA expression in
adenocarcinoma H460 and A549 cells in a time- and dose-
dependent manner. In both cell lines, an increase in NAG-1
mRNA levels could be observed as early as 4 h after the
addition of 2.5 M AHPN. In H460, optimal induction of
NAG-1 mRNA was reached 16 h after addition of AHPN,
whereas a concentration as low as 0.3 M AHPN was able to
induce NAG-1 mRNA.
Induction of NAG-1 Protein by AHPN. NAG-1 has been
reported to be synthesized as a homodimeric precursor of
about 80 kDa that is processed by proteolysis and secreted as
a homodimer consisting of two 14-kDa peptides. Western
blot analysis of total cellular protein from AHPN-treated
H460 cells demonstrated that the level of 40-kDa precursor
Fig. 1. AHPN is an effective inducer of NAG-1 mRNA expression in
several carcinoma cell lines. A, comparison of the effects of the RAR-
selective pan-agonist TTAB (RARsel), the RXR-selective pan-agonist
SR11217 (RXRsel), AHPN, and the reported anti-AP-1-selective retinoid
SR11302 (anti-activator protein 1 sel) on NAG-1 mRNA expression in
human lung adenocarcinoma H460 cells. B and C, effects of AHPN (2.5
M) and RARsel (1 M) on NAG-1 mRNA expression in several carci-
noma cell lines. Carcinoma cells were treated with the indicated retinoid.
After 16 h cells were collected and RNA isolated. Total RNA (20 g) was
examined by Northern blot analysis using radiolabeled probes for NAG-1
and GPDH.
Fig. 2. A and B, time course and concentration dependence of the induc-
tion of NAG-1 mRNA in lung adenocarcinoma H460 and A549 cells by
AHPN. Cells were treated with 2.5 M AHPN at the times indicated or
for 24 h at the concentrations indicated. Total RNA (30 g) was isolated
and examined by Northern blot analysis using radiolabeled probes for
NAG-1 and GPDH.
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protein increased in a time-dependent manner (Fig. 3A). A
24-fold induction in NAG-1 protein was observed 16 h after
the addition of AHPN. Analysis of NAG-1 released into the
medium showed a similar accumulation of the 14-kDa pro-
cessed NAG-1 protein. This induction of NAG-1 protein was
only observed with AHPN and not with the RAR- or RXR
pan-agonists (Fig. 3B).
Because both AHPN and NAG-1 have been reported to
promote apoptosis in certain cell lines, cells were treated
with NAG-1 protein to determine whether the induction of
apoptosis was caused by the synthesis and release of NAG-1
protein. However, treatment of H460 and A549 cells with
NAG-1 did not affect proliferation or induce apoptosis and
did not synergize with or inhibit AHPN-induced apoptosis
(data not shown).
Regulation of NAG-1 at the Level of RNA Stability.
AHPN has been reported to regulate gene expression by
transcriptional and post-transcriptional mechanisms (Rishi
et al., 1999; Sun et al., 2000; Sakaue et al., 2001). The
3.5-kilobase 5-promoter flanking region of the NAG-1 gene
has been reported to contain several DNA elements involved
in its regulation (Baek et al., 2001a; Wong et al., 2002). Using
a reporter under the control of this regulatory region, we
examined the effect of AHPN on transcriptional activation.
AHPN had little effect on this transcriptional activation
(data not shown), suggesting that it does not control the
transcription of this gene through elements contained in this
3.5-kilobase region.
To determine whether NAG-1 was regulated by AHPN at a
post-transcriptional level, we examined its effect on NAG-1
mRNA stability. H460 cells were treated with AHPN or ve-
hicle for 8 h; transcription was then inhibited by the addition
of actinomycin D and at different time intervals the level of
NAG-1 RNA determined by Northern blot analysis. Figure 4,
A and B, demonstrates that the half-life of NAG-1 mRNA in
control H460 cells was 27 min compared with 3.5 h in AHPN-
treated cells. These results suggest that this increase in
stability of NAG-1 mRNA is a major factor in the induction of
NAG-1 expression by AHPN.
The induction of NAG-1 mRNA was found to be sensitive to
cycloheximide because no increase in NAG-1 mRNA was ob-
served after AHPN treatment in the presence of cycloheximide
(Fig. 4C), suggesting that the effect of AHPN on NAG-1 is
dependent on de novo protein synthesis. Cycloheximide may
block the synthesis of a protein that stabilizes NAG-1 mRNA.
The induction of several genes, including Egr-1 and Nur77,
Fig. 3. AHPN causes an increase in cellular NAG-1 precursor protein and
active NAG-1 in the medium. A, H460 cells were treated with AHPN and
at the indicated times cellular proteins and proteins secreted into the
medium were examined by Western blot analysis using a NAG-1-specific
antibody. In cellular extracts the antibody recognized the 40-kDa
NAG-1 precursor and in medium the processed 14-kDa NAG-1 protein.
B, cellular protein from H460 cells treated with the RAR- and RXR-pan-
agonist, and AHPN (1 M for 24 h) was examined by Western analysis for
the presence of NAG-1.
Fig. 4. Effect of AHPN on the stability of NAG-1 mRNA. A, H460 cells
were treated with AHPN for 8 h and subsequently with actinomycin D (5
g/ml). At the indicated times, RNA was isolated and examined by
Northern blot analysis with a radiolabeled probe for NAG-1 and GPDH.
Poly(A) RNA was used in the case of untreated cells (F) and total RNA
for AHPN-treated cells (f). B, hybridization signals were quantitated
with a PhosphorImage analyzer using ImageQuant software as described
under Materials and Methods. The relative level of NAG-1 RNA (relative
to the level of GPDH) was calculated, and the results plotted as the
percentage of the RNA level present at time 0 of actinomycin D addition.
C, cycloheximide inhibits the induction of NAG-1 mRNA by AHPN. Cy-
cloheximide (5 g/ml; CHX) or vehicle was added 30 min before H460 or
A549 cells were treated with AHPN (2.5 M). After 8 h, RNA was isolated
and examined by Northern blot analysis for NAG-1 mRNA expression.
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by AHPN is blocked by the mitogen-activated protein kinase/
extracellular signal-regulated kinase 1 (MEK1) inhibitor
PD98059 (Sakaue et al., 2001); however, inhibition of the
MEK1/ERK1/2 signaling pathway had little effect on AHPN-
mediated induction of NAG-1 (data not shown), suggesting
that this induction is regulated by an ERK1/2-independent
mechanism.
Induction of NAG-1 Expression by Retinoids in Nor-
mal HTBE Cells. Next, the effect of several retinoids on
NAG-1 expression was examined in normal HTBE cells. In
contrast to human lung carcinoma H460 cells, the RAR pan-
agonist TTAB, retinoic acid, and AHPN all induced NAG-1
mRNA expression in normal HTBE cells (Fig. 5A). TTAB was
more effective than RA and AHPN in inducing NAG-1,
whereas the RXR-selective retinoid SR11217 had little effect
on NAG-1 expression. In contrast to H460 cells, AHPN did
not induce apoptosis in HTBE (data not shown) in agreement
with previous studies (Sun et al., 2002). Clearly, the speci-
ficity by which retinoids induce NAG-1 expression in normal
HTBE cells differed substantially from that of H460 cells,
suggesting that in these two cell types NAG-1 expression is
regulated by two different mechanisms. The induction of
NAG-1 mRNA by TTAB occurred in a dose-dependent man-
ner (Fig. 5B). TTAB was able to induce NAG-1 at concentra-
tions as low as 1 nM. The enhancement in NAG-1 mRNA was
accompanied by an increase in NAG-1 proteins levels (Fig.
5C).
NAG-1 Expression Is Associated with Normal Differ-
entiation of HTBE Cells. Previous studies have shown that
retinoids are essential for the normal differentiation of
HTBE cells. In the absence of retinoids, HTBE cells in vivo as
well in vitro undergo squamous differentiation, whereas in
the presence of retinoids cells differentiate into mucosecre-
tory and ciliated cells. (Koo et al., 1999). As shown in Fig. 6A,
HTBE cells grown to confluence in the absence of retinoic
acid expressed little NAG-1 mRNA. Subsequent treatment
with retinoic acid caused a rapid increase in the level of
NAG-1 mRNA expression. An increase in NAG-1 mRNA
could be observed as early as 12 h after the addition of
Fig. 5. A, induction of NAG-1 mRNA expression by retinoid receptor-
selective retinoids. Normal HTBE cells were cultured as described under
Materials and Methods. At day 7, cells were treated with either retinoic
acid, the RAR-selective pan-agonist TTAB (100 nM; RARsel), the RXR-
selective pan-agonist SR11217 (1 M; RXRsel), or AHPN (1 M). RNA
was examined by Northern blot analysis using 32P-radiolabeled probes
for NAG-1. B, dose dependence of NAG-1 mRNA induction by the RAR-
pan-agonist TTAB in normal HTBE cells. HTBE cells were grown in
Transwell dishes in the presence of the indicated concentration of TTAB.
Total RNA was isolated and examined by Northern analysis using 32P-
radiolabeled probes for NAG-1 and GPDH. C, induction of NAG-1 protein
by the RAR-pan-agonist TTAB in normal HTBE cells.
Fig. 6. A, induction of NAG-1 mRNA expression in normal HTBE cells by
retinoic acid. Cells were grown in Transwell dishes in the absence of
retinoids for 7 days and then in the presence or absence of 1 M RA. At
different time intervals cells were collected and RNA isolated. Total RNA
(10 g) was examined by Northern blot analysis using 32P-radiolabeled
probe for NAG-1. B, expression of NAG-1 in relation to squamous and
mucous cell differentiation. The relative level of NAG-1, transglutami-
nase type I (TGase I), and MUC2 mRNA expression was calculated and
plotted as function of time. NAG-1 and TGase I mRNA expression were
determined by Northern blot analysis, whereas MUC2 mRNA expression
was analyzed in the same samples by reverse transcription-polymerase
chain reaction as described under Materials and Methods. The mRNA
levels (relative to that of 18S rRNA) were determined by densitometry.
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retinoic acid and accompanied the suppression of transglu-
taminase I mRNA expression, a squamous cell-specific
marker (Fig. 6B). The induction of NAG-1 mRNA preceded
the increase in the expression of the mucin gene MUC2,
which was first observed at 24 h of retinoic acid treatment in
agreement with a previous report (Koo et al., 1999). These
results suggest an association of NAG-1 expression with the
induction of the normal pathway of differentiation in HTBE
cells.
To determine whether NAG-1 had any effect on differenti-
ation, HTBE cells were treated with NAG-1 in the presence
or absence of retinoic acid. No significant differences were
observed between treated and untreated cells with regard to
the expression of transglutaminase I and MUC-2 (data not
shown).
In Vivo Localization of NAG-1. To determine the ex-
pression of NAG-1 in the normal tracheobronchial epithe-
lium, sections of normal human trachea and several tumor
tissues from adeno-, small cell, large cell, and squamous cell
carcinomas were stained with an anti-NAG-1 antiserum. As
shown in Fig. 7, the columnar cells in normal tracheobron-
chial epithelium stained positively for NAG-1 protein,
whereas no staining was observed in basal cells or in any of
the tumor sections analyzed regardless of the histological
subtype of the tumor (Fig. 7, A and B; data not shown). In the
normal epithelium, staining was most pronounced in ciliated
cells. A previous study (Sueoka et al., 2000) showed that
when small sections of human trachea are cultured in the
presence of retinoic acid the normal architecture of the tra-
cheobronchial epithelium is maintained; however, when sec-
tions are cultured in the absence of retinoic acid the epithe-
lium becomes squamous metaplastic. As shown in Fig. 7C,
the epithelium of sections cultured in the presence of retinoic
acid stained positively for NAG-1, whereas sections cultured
in the absence of retinoic acid stained negatively for NAG-1
(Fig. 7D). These results demonstrate that NAG-1 expression
is associated with the normal tracheobronchial epithelium
and is not expressed in basal cells or in squamous differen-
tiated cells. These observations are in agreement with the
findings shown in Fig. 6.
Discussion
In this study, we demonstrate that treatment of human
lung carcinoma and normal HTBE cells with retinoids dra-
matically induces the expression of NAG-1. The induction of
NAG-1 in carcinoma and normal cells is dependent on the
type of retinoid used and seems to be regulated by distinct
mechanisms and associated with different biological pro-
cesses.
Previous studies have shown that the synthetic retinoid
AHPN inhibits cell proliferation and is an effective inducer of
apoptosis in several human lung carcinoma and other carci-
noma cell lines (Shao et al., 1995; Adachi et al., 1998; Rishi et
al., 1999; Zhao et al., 2001; Sun et al., 2002). Although AHPN
can bind selectively to the RAR receptor and weakly acti-
vate transcription through this receptor, many of its re-
sponses associated with inhibition of cellular proliferation
and induction of apoptosis have been found not to involve
RAR or RXR nuclear receptor-mediated signaling pathways.
In this study, we demonstrate that AHPN is an effective
inducer of NAG-1 expression in lung carcinoma H460 and
A549 cells and several other carcinoma cell lines. The time
course and concentration dependence of this induction are
very similar to those reported for AHPN-induced apoptosis
and induction of other genes, including GADD45 and
MYD118 (Adachi et al., 1998; Sakaue et al., 1999). The in-
duction of NAG-1 is rather specific for AHPN because in most
cell lines retinoic acid or the RAR- or RXR-pan-agonist were
unable to induce NAG-1 mRNA. These results suggest that
AHPN regulates NAG-1 expression by a mechanism that is
Fig. 7. Immunohistochemical localization of NAG-1 protein in normal
human bronchus and human lung carcinoma. Sections of human bron-
chus and lung carcinoma were examined by immunohistochemical anal-
ysis as described under Materials and Methods using a specific anti-
NAG-1 antiserum. Preimmune serum was used in controls and did not
show any staining (data not shown). A, normal human bronchus. B,
human lung adenocarcinoma. C, human bronchus cultured in the pres-
ence of retinoic acid; normal pseudostratified epithelium is maintained.
D, human bronchus cultured in the absence of retinoic acid; epithelium
becomes squamous metaplastic.
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independent of retinoid receptors. Many retinoids, including
the RXR pan-agonist SR11217 and SR11302, have been re-
ported to exhibit anti-AP-1 activity (Fanjul et al., 1994).
Because these retinoids do not affect NAG-1 expression in
H460 cells, the induction of NAG-1 seems not to involve the
anti-AP-1 activity of retinoids (Fig. 1A).
AHPN has been reported to regulate gene expression by
transcriptional as well as post-transcriptional mechanisms
(Rishi et al., 1999; Sakaue et al., 1999, 2001). In H460 cells,
AHPN causes an 8-fold increase in the half-life of NAG-1
mRNA, from 27 min in control cells to3.5 h in treated cells.
These results suggest that the increase in NAG-1 mRNA
expression by AHPN may be largely regulated by a post-
transcriptional mechanism and be caused by increased sta-
bility of NAG-1 mRNA. Stability of mRNAs can be mediated
by different mechanisms. The control of mRNA stability can
involve adenylate/uridylate-rich instability elements in the
3-UTR or specific RNA stemloop motifs (Chen and Shyu,
1995; Ross, 1996). Specific mRNA binding proteins interact-
ing with such motifs may protect NAG-1 RNA from degrada-
tion by endo- and exonucleases, thereby increasing RNA sta-
bility. Inversely, increased stability might be caused by a
reduction in the level of proteins that destabilize NAG-1
mRNA. Recently, tristetraproline (TTP) has been reported to
interact with specific AU-rich motifs and target certain
mRNAs such as tumor necrosis factor- mRNA for enhanced
degradation (Lai et al., 2000). Interestingly, the 3-UTR of
human NAG-1 mRNA contains three AU-rich elements that
may play a role in determining the stability of NAG-1 mRNA
(Yokoyama-Kobayashi et al., 1997). However, the induction
of NAG-1 seems to be unrelated to TTP because TTP expres-
sion was enhanced severalfold rather than decreased in
AHPN-treated H460 cells (Sakaue et al., 2001). Therefore,
the stabilization of NAG-1 mRNA may involve interaction
with other proteins. Our observation that cycloheximide sup-
presses the induction of NAG-1 mRNA by AHPN would be in
agreement with the hypothesis that it inhibits the synthesis
of a protein stabilizing NAG-1 RNA rather than of an RNA
destabilizing protein. In addition to NAG-1 mRNA, AHPN
has been reported to enhance the stability of several other
RNAs, including GADD45 and MYD118 mRNA (Rishi et al.,
1999; Sakaue et al., 1999). In the case of GADD45, a 45-base
pair region in the 5-UTR was found to be involved in the
increased stability caused by AHPN (Rishi et al., 1999).
NAG-1 expression has been reported to be regulated by
p53-dependent and -independent mechanisms. Recent stud-
ies have identified two p53 binding sites in the NAG-1 pro-
moter regulatory region and one p53-repressor element that
suppresses p53-mediated transactivation (Wong et al., 2002).
The induction of NAG-1 in colon and mammary carcinoma
cells by resveratrol (Baek et al., 2002) and irradiation (Li et
al., 2000), respectively, is regulated through a p53-dependent
mechanism. However, nonsteroidal anti-inflammatory
agents have been shown to enhance NAG-1 by a cyclooxygen-
ase-1/2- and p53-independent mechanism (Baek et al.,
2001a,b). The induction of NAG-1 in human glioblastoma by
anoxia occurs also independently of p53 (Albertoni et al.,
2002). Although AHPN induces p53 in H460 and other car-
cinoma cell lines, the induction of NAG-1 by AHPN does not
require p53 induction because AHPN induces NAG-1 in cell
lines, including H1355 and BT549, which contain mutant
p53. Previously, we have shown that several other genes,
including GADD45, MyD118, and Egr-1, are induced by
AHPN independently of the p53 status (Sakaue et al., 1999,
2001). However, we cannot rule out that in certain cell lines
p53 may act synergistically with the p53-independent mech-
anism (Sun et al., 1999). The latter is supported by the higher
levels of NAG-1 expression observed in HT1080-p53wt com-
pared with HT1080-p53mt cells (Fig. 1B).
In contrast to lung carcinoma H460 cells, both retinoic acid
and the RAR pan-agonist are able to induce effectively (10–
30-fold) the expression of NAG-1 mRNA in normal HTBE
cells. AHPN treatment also caused a small increase in
NAG-1 expression but in contrast to carcinoma cells AHPN
does not induce apoptosis in normal HTBE cells in agreement
with previous studies (Sun et al., 2002). HTBE cells grown in
the absence of retinoids undergo squamous differentiation,
as characterized by the expression of the squamous cell
markers transglutaminase type I and cornifin, whereas treat-
ment with retinoic acid, TTAB, or AHPN induces mucocili-
ated cell differentiation as indicated by the enhanced expres-
sion of several genes, including RAR, CYP26, MUC2, and
MUC5AC (Koo et al., 1999; Kim et al., 2000). Our results
show that the increase in NAG-1 mRNA expression in HTBE
accompanies the inhibition of the squamous phenotype and
the induction of the mucociliated cell differentiation. In
HTBE cells, NAG-1 expression is therefore associated with
the induction of normal differentiation. This conclusion is
supported by immunohistochemical analysis of sections from
normal and squamous metaplastic tracheobronchial epithe-
lium. In the normal tracheobronchial epithelium NAG-1
seems to be most highly expressed in the ciliated cells. The
precise role(s) of NAG-1 in the normal tracheobronchial epi-
thelium is not yet fully understood. Clearly, in normal cells
NAG-1 is not associated with apoptosis. Preliminary studies
did not reveal any influence of NAG-1 on the expression of
several differentiation markers in HTBE cells. The rapid
induction seen in HTBE after the addition of retinoic acid
occurs at a time when cell cultures undergo a lot of remod-
eling, suggesting that NAG-1 may play a role in this process.
Another study has proposed a similar role for NAG-1 during
regeneration in mouse liver (Hsiao et al., 2000). The mecha-
nism by which NAG-1 transduces its signal is still poorly
understood but probably involves interaction with cell sur-
face receptors. Future identification of such receptors will
help to determine which cells are targets for NAG-1 action.
Although the precise biological functions of NAG-1 are not
yet well understood, roles in inflammation, embryonic devel-
opment, and tumorigenesis have been suggested. NAG-1 is
highly expressed in activated macrophages and may play a
role in late anti-inflammatory responses (Bootcov et al.,
1997). Overexpression of NAG-1 has been reported to inhibit
cell proliferation and induce apoptosis in mammary carci-
noma MDA-MB-468 and colon carcinoma HCT-116 cells (Li
et al., 2000; Baek et al., 2001b), whereas other studies
showed little effect of NAG-1 on proliferation of glioblastoma
cells (Albertoni et al., 2002). Addition of human NAG-1 to
human lung carcinoma H460 and A549 cells did not affect
proliferation or apoptosis (data not shown), suggesting that
treatment with NAG-1 alone may not be sufficient to induce
apoptosis in these cells. AHPN increases the expression of
many growth-suppressor and apoptosis-promoting genes (Li
et al., 1996; Rishi et al., 1999; Sakaue et al., 1999, 2001; Sun
et al., 2000). It seems likely that the growth inhibitory,
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apoptosis-inducing, and antitumorigenic effects of AHPN de-
pend on the synergistic/cooperative action of many proteins.
Several studies have recently demonstrated that expres-
sion of NAG-1 greatly inhibits the tumorigenic capacity of
colon carcinoma and glioblastoma cells in mice (Baek et al.,
2001b; Albertoni et al., 2002). It has been suggested that the
antitumorigenic activity of NAG-1 may involve both auto-
crine and paracrine mechanisms. The latter may involve
antiangiogenic effects of NAG-1. The antitumorigenic effects
of NAG-1 are of particular interest to the reported inhibition
of tumor growth by AHPN in mice (Lu et al., 1997). The
linkage between NAG-1 induction and AHPN revealed in this
study provides a new molecular mechanism that may con-
tribute to the antitumorigenic activities of AHPN.
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